» Articles » PMID: 16183706

TPA023 [7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine], an Agonist Selective for Alpha2- and Alpha3-containing GABAA Receptors, is a Nonsedating Anxiolytic in Rodents and Primates

Abstract

7-(1,1-Dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo[4,3-b]pyridazine (TPA023) is a triazolopyridazine that binds with equivalent high (subnanomolar) affinity to the benzodiazepine binding site of recombinant human GABA(A) receptors containing an alpha1, alpha2, alpha3, or alpha5 subunit but has partial agonist efficacy at the alpha2 and alpha3 subtypes and essentially antagonist efficacy at the alpha1 and alpha5 subtypes. In rats, TPA023 gave time- and dose-dependent occupancy after oral dosing, with 50% occupancy corresponding to a dose of 0.42 mg/kg. It has anxiolytic-like activity in unconditioned (elevated plus maze) and conditioned (fear-potentiated startle and conditioned suppression of drinking) rat models of anxiety with minimum effective doses (MED; 1-3 mg/kg) corresponding to 70 to 88% occupancy. However, there was no appreciable sedation in a response sensitivity (chain-pulling) assay at a dose of 30 mg/kg, resulting in 99% occupancy. Similarly, TPA023 was robustly anxiolytic in the squirrel monkey conditioned emotional response assay, with a MED of 0.3 mg/kg, but did not produce any sedation in a lever-pressing test of sedation even at 10 mg/kg. TPA023 produced no impairment in performance in the mouse Rotarod assay, and there was only a mild interaction with ethanol. In addition to anxiolytic-like efficacy, TPA023 had anticonvulsant activity in a mouse pentylenetetrazole seizure model. Finally, TPA023 did not cause precipitated withdrawal in mice treated for 7 days with the nonselective agonist triazolam, nor did N-methyl-beta-carboline-3-carboxamide (FG 7142) precipitate withdrawal in mice treated for 7 days with TPA023. In summary, the novel alpha2/alpha3-selective efficacy profile of TPA023 translates into a nonsedating anxiolytic profile that is distinct from nonselective agonists.

Citing Articles

Antinociceptive Effects of 2/3-Subtype-Selective GABA Receptor Positive Allosteric Modulators KRM-II-81 and NS16085 in Male Rats: Behavioral Specificity.

Lewter L, Woodhouse K, Tiruveedhula V, Cook J, Li J J Pharmacol Exp Ther. 2024; 391(3):389-398.

PMID: 38670800 PMC: 11585310. DOI: 10.1124/jpet.123.002070.


Therapeutic effects of KRM-II-81, positive allosteric modulator for α2/3 subunit containing GABA receptors, in a mouse model of Dravet syndrome.

Nakakubo S, Hiramatsu Y, Goto T, Kimura S, Narugami M, Nakajima M Front Pharmacol. 2023; 14:1273633.

PMID: 37849734 PMC: 10577232. DOI: 10.3389/fphar.2023.1273633.


Modulators of GABA receptor-mediated inhibition in the treatment of neuropsychiatric disorders: past, present, and future.

Thompson S Neuropsychopharmacology. 2023; 49(1):83-95.

PMID: 37709943 PMC: 10700661. DOI: 10.1038/s41386-023-01728-8.


Pharmacological modulation of conditioned fear in the fear-potentiated startle test: a systematic review and meta-analysis of animal studies.

Groenink L, Verdouw P, Zhao Y, Ter Heegde F, Wever K, Bijlsma E Psychopharmacology (Berl). 2023; 240(11):2361-2401.

PMID: 36651922 PMC: 10593622. DOI: 10.1007/s00213-022-06307-1.


Pronounced antiseizure activity of the subtype-selective GABA positive allosteric modulator darigabat in a mouse model of drug-resistant focal epilepsy.

Gurrell R, Iredale P, Evrard A, Duveau V, Ruggiero C, Roucard C CNS Neurosci Ther. 2022; 28(11):1875-1882.

PMID: 35965432 PMC: 9532903. DOI: 10.1111/cns.13927.